J75 Stock Overview
A clinical-stage biotechnology company with a focus on developing immunotherapies that transform patients' lives. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Kineta, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.44 |
| 52 Week High | US$2.50 |
| 52 Week Low | US$0.21 |
| Beta | 0 |
| 1 Month Change | -5.98% |
| 3 Month Change | -34.33% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -80.70% |
Recent News & Updates
Recent updates
Shareholder Returns
| J75 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 3.3% | 1.0% | -0.6% |
| 1Y | n/a | -10.5% | 9.2% |
Return vs Industry: Insufficient data to determine how J75 performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how J75 performed against the German Market.
Price Volatility
| J75 volatility | |
|---|---|
| J75 Average Weekly Movement | 28.9% |
| Biotechs Industry Average Movement | 6.7% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: J75's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: J75's weekly volatility has increased from 23% to 29% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 12 | n/a | kinetabio.com |
Kineta, Inc. is a clinical-stage biotechnology company with a focus on developing immunotherapies that transform patients' lives. It focuses on developing potentially differentiated immunotherapies that address the challenges with current cancer therapy. The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug.
Kineta, Inc. Fundamentals Summary
| J75 fundamental statistics | |
|---|---|
| Market cap | €8.87m |
| Earnings (TTM) | -€16.46m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.5x
P/E RatioIs J75 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| J75 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$9.02m |
| Gross Profit | -US$9.02m |
| Other Expenses | US$8.26m |
| Earnings | -US$17.28m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.41 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -6.6% |
How did J75 perform over the long term?
See historical performance and comparison